This article has Open Peer Review reports available.
A 43-year-old woman on triptorelin presenting with pseudotumor cerebri: a case report
© Bhatt et al.; licensee BioMed Central Ltd. 2012
Received: 13 December 2011
Accepted: 3 May 2012
Published: 3 May 2012
To the best of our knowledge, this is the first time triptorelin has been reported to cause benign intracranial hypertension.
A 43-year-old Caucasian woman who suffered from chronic menorrhagia was started on triptorelin, a gonadotrophin-releasing hormone analogue. Three days later, she developed gradually worsening headaches accompanied by bilateral visual disturbance. Examination revealed bilateral papilledema and enlarged blind spots on her visual fields. A diagnosis of benign intracranial hypertension was made and confirmed on magnetic resonance imaging.
We recommend that patients at high risk (women who are overweight and of reproductive age) who are using any gonadotrophin-releasing hormone analogue (for example, triptorelin) should be periodically monitored for the possible development of benign intracranial hypertension.
A woman with menorrhagia was started on triptorelin, a synthetic gonadotrophin-releasing hormone analogue, mainly used in the treatment of prostate carcinoma and endometriosis.
Three days later, she developed gradually worsening headaches accompanied by bilateral visual disturbance. An examination revealed bilateral papilledema and enlarged blind spots on her visual fields. A diagnosis of benign intracranial hypertension (BIH) was made and confirmed on magnetic resonance imaging (MRI).
A 43-year-old Caucasian woman was treated for chronic menorrhagia with a Mirena® coil and traxenamic acid with no success. Her gynecologist started her on triptorelin. Three days after the first dose, she attended our eye centre casualty with progressively worsening headaches accompanied by visual disturbances. She had no past medical history of note, and was on no other medications at the time of presentation.
She was urgently referred to our neurology team for a lumbar puncture. Her CSF opening pressure was significantly high at 43 cm but a CSF analysis was normal. A diagnosis of BIH was made and she had further therapeutic CSF drainage done at the same time. She was advised to discontinue triptorelin and start oral acetazolamide 250 mg four times a day, although this was only given for seven days and stopped, as our patient could not tolerate it.
BIH, also known as pseudotumor cerebri, has an incidence of 1.6 to 3.5 per 100,000 in women and is much higher at 7.9 to 20 per 100,000 in women who are overweight and of reproductive age . Although by definition the etiology of BIH is unknown, a plethora of drugs and systemic conditions are associated with this condition [2, 3]. To explain the mechanism of BIH, some hypotheses have been put forward. These include the link between BIH and relatively obstructive segments in the distal transverse sinus, unrecognized sinus thrombosis (undetected by MRI or MRV scans), or the presence of increased arterial inflow with an accompanying low-grade stenosis of the transverse sinus [2–5].
Administration of triptorelin initially stimulates the anterior pituitary gland to release the gonadotrophins luteinizing hormone and follicle-stimulating hormone. However, its sustained use leads to their suppression.
To explain the BIH in this case, we speculate that the Triptorelin-induced initial surge of gonadal steroids may have caused non-occlusive thrombosis of the dural venous sinuses by creating a venous hypertensive state and impeding CSF drainage.
BIH usually develops several weeks to months after the intake of the offending medication . In our case, the dramatic presentation and the very high CSF opening pressure (43 cm) suggest a possible idiosyncratic effect in our patient. Nevertheless, after stopping the drug, our patient’s visual improvement and the resolution of the papilledema were also very dramatic. Such a causal relationship strongly suggests triptorelin to be the cause of the BIH.
BIH has also been documented with the use of leuprorelin, which is similar in structure to triptorelin, and this only strengthens the basis of our report . In 1994, Radhakrishnan et al.  reviewed the literature on BIH associated with other diseases and with drugs. Within their study, the authors insisted that the following criteria should be met to include the disease or drug within their list of causally related associations: at least two cases should have been described; the reported cases should have met all the criteria for the diagnosis of idiopathic intracranial hypertension; and intracranial dural sinus thrombosis should have been ruled out with reasonable certainty.
Therefore gonadotrophin-releasing hormone analogues fulfill the authors’ criteria as a causative agent for BIH .
We recommend that patients at high risk (women who are overweight and of reproductive age) who are using any gonadotrophin-releasing hormone analogue (for example, triptorelin) should be periodically monitored for the possible development of BIH.
Written informed consent was obtained from the patient for publication of this manuscript and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Friedman DI, Jacobson DM: Benign intracranial hypertension. J Neuroophthalmol. 2004, 24 (2): 138-145. 10.1097/00041327-200406000-00009.View ArticlePubMedGoogle Scholar
- Wall M: Benign intracranial hypertension (pseudotumor cerebri). Curr Neurol Neurosci Rep. 2008, 8 (2): 87-93. 10.1007/s11910-008-0015-0.View ArticlePubMedGoogle Scholar
- Miller NR, Newman NJ: The essentials: Walsh & Hoyt's clinical neuro-ophthalmology. 1999, Williams & Wilkins, Baltimore; London, 5Google Scholar
- Skau M, Brennum J, Gjerris F, Jensen R: What is new about benign intracranial hypertension? An updated review of mechanism and treatment. Cephalalgia. 2006, 26 (4): 384-399. 10.1111/j.1468-2982.2005.01055.x.View ArticlePubMedGoogle Scholar
- Bateman GA, Stevens SA, Stimpson J: A mathematical model of benign intracranial hypertension incorporating increased arterial inflow and variable venous outflow collapsibility. J Neurosurg. 2009, 110 (3): 446-456. 10.3171/2008.6.17609.View ArticlePubMedGoogle Scholar
- Lochhead J, Elston JS: Doxycycline induced intracranial hypertension. BMJ. 2003, 326 (7390): 641-642. 10.1136/bmj.326.7390.641.View ArticlePubMedPubMed CentralGoogle Scholar
- Boot JH: Pseudotumour cerebri as a side effect of leuprorelin acetate. Ir J Med Sci. 1996, 165 (1): 60-10.1007/BF02942809.View ArticlePubMedGoogle Scholar
- Radhakrishnan K, Ahlskog JE, Cross SA, Kurland LT, O'Fallon WM: Benign intracranial hypertension (pseudotumor cerebri). Descriptive epidemiology in Rochester, Minn, 1976 to 1990. Arch Neurol. 1993, 50 (1): 78-80. 10.1001/archneur.1993.00540010072020.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.